Thomas Van Dyke, DDS, PhD, CAGS Periodontology
Primary Audience(s): Dentist
Additional Audience(s): Hygienist, EFDA/Dental Assistant
CE Credits: 1.5
Recent studies have suggested that periodontal diseases are inflammatory diseases initiated by bacterial biofilm; infectious inflammatory diseases. Further, dysbiosis of the oral microbiome is a result of inflammation and that dysbiosis further amplifies the inflammatory cascade. This distinction implies that it is the host response to the biofilm that destroys the periodontium in the pathogenesis of the disease. This paradigm shift has broad implications for the prevention and treatment of periodontitis. As our understanding of pathways of inflammation has matured, a better understanding of the molecular basis of resolution of inflammation, which is distinct from pharmacologic anti-inflammation, has emerged. Resolution of inflammation is an active; receptor agonist mediated well-orchestrated return of tissue homeostasis, not inhibition of proinflammatory pathways. The isolation and characterization of endogenous lipid mediators of resolution, called lipoxins and resolvins, has open new doorways for the management of periodontitis including periodontal regeneration. This presentation will review resolution of inflammation in the context of periodontal disease and clarify the role of bacteria in periodontitis and explore therapeutic targets.
- Understand the relationship between inflammation, bone loss and tissue regeneration in periodontitis.
- Explain the mechanism of action of periodontal regeneration; why it works and doesn’t work in different situations.
- Discuss potential modifications of treatment regimens for the patient with periodontitis to control inflammation, prevent further damage and achieve true periodontal regeneration.
- Understand the biologic basis of the relationship between periodontitis and systemic disease.
- Develop a working knowledge of inflammatory interactions leading to and linking the common diseases of aging.
- Discuss the modifications of treatment for the patient with periodontitis and complicating systemic disease.
Thomas Van Dyke, D.D.S., Ph.D. is Senior Vice President for Clinical and Translational Research and Senior Member of Staff at the Forsyth Institute in Cambridge, MA, and Professor of Oral; Medicine, Infection and Immunity, Harvard University Faculty of Medicine. D.D.S., Case Western Reserve University; M.S., SUNY Buffalo in Oral Sciences; Periodontics Certificate, SUNY Buffalo; Ph.D., SUNY Buffalo in Oral Biology, and two doctoral degrees honorus causa; Justis Liebig University, Giessen and University of Copenhagen. Balint Orban Memorial Prize for Research in Periodontology, Diplomate of the American Board of Periodontology, IADR Award for Basic Research in Periodontology, the Norton Ross Award for Excellence in Clinical Research, William J. Gies Periodontology Award. He serves on numerous editorial boards has edited two volumes of Periodontology 2000. President of the International Association of Periodontology (1997-1999). Dr. Van Dyke has published 370+ original articles, and numerous abstracts and book chapters. Member of the American/International Association of Dental Research, American Academy of Periodontology, International Academy of Periodontology, American Association for the Advancement of Science, American Society of Microbiology, IADR Periodontal Research Group, American Dental Association, and American Association of Immunologists. His research interests are the structural and functional relationship of abnormalities of the inflammatory process with focus on phagocytic cells and microorganisms, in the etiology and pathogenesis of periodontal and other infectious-inflammatory diseases. Dr. Van Dyke is also involved in clinical research and clinical trials focusing on drug treatment for periodontal disease and local delivery systems. The remainder of his time is devoted to training of fellows and administration. He is best known for his work on the pathogenesis of juvenile periodontal diseases, resolution of inflammation in periodontitis, and clinical research.